share_log

Highmark Interactive Inc. Reports Q2 2022 Financial Results and Operational Developments

Highmark Interactive Inc. Reports Q2 2022 Financial Results and Operational Developments

Highmark Interactive Inc.報告2022年第二季度財務業績和運營發展
Accesswire ·  2022/08/22 21:05

TORONTO, ON / ACCESSWIRE / August 22, 2022 / Highmark Interactive Inc. (TSXV:HMRK) (the "Company" "Highmark"), a global leader in digital health technologies, will report its fiscal second quarter results for the three and six months ended June 30, 2022.

多倫多,on/ACCESSWIRE/2022/全球領先的數字健康技術公司Highmark Interactive Inc.(TSXV:HMRK)將公佈截至2022年6月30日的三個月和六個月的第二財季業績。

Operational Developments During Fiscal Second Quarter 2022.

2022年第二財季的業務發展.

Highmark Interactive Inc. continued to build on its momentum from the first quarter of its EQ Remote Monitoring (RPM) solution for orthopedic clinicians in the United States with its June 8, 2022 announcement collaborating with Urgent Orthopedic Care Inc. (UOC). UOC is a multi-clinic orthopedic organization which manages over 10,000 patients annually. Highmark's EQ RPM platform is ideal for pre & post-surgical monitoring, in addition to between clinician visits. Highmark's EQ Balance is FDA-cleared software as a Medical Device (SAMD). Remote physiologic monitoring (RPM) is a recently added reimbursement code by Medicare in the United States and now with many commercial issuers. RPM provides the clinician with a tool for more precise care and better patient outcomes. Highmark is pleased to announce the UOC partnership is now live as of August 2022.

Highmark Interactive Inc.繼續在其面向美國整形外科臨牀醫生的EQ遠程監控(RPM)解決方案的第一季度取得進展的基礎上,於2022年6月8日宣佈與緊急整形外科護理公司(UoC)合作。UOC是一家多診所整形外科組織,每年管理超過10,000名患者。Highmark的EQ RPM平臺是手術前和手術後監測的理想選擇,此外還可以在臨牀醫生就診之間進行監測。Highmark的EQ Balance是FDA批准的醫療設備軟件(SAMD)。遠程生理監測(RPM)是美國聯邦醫療保險最近增加的一種報銷代碼,現在許多商業發行商都在使用。RPM為臨牀醫生提供了一種更精確的護理和更好的患者結果的工具。Highmark很高興地宣佈,UOC的合作伙伴關係現已於2022年8月生效。

As noted in Highmark's February 3, 2022 press release, in adopting Highmark's EQ Remote Monitoring platform, a typical surgeon can generate an additional USD$200,000 in revenue annually based on billing approximately $270 per patient with at least 735 patients per year, all while identifying and addressing concerns earlier that can minimize or prevent significantly more expensive downstream costs.

正如Highmark在2022年2月3日的新聞稿中指出的那樣,採用Highmark的EQ遠程監控平臺後,一名典型的外科醫生每年可以為每個患者支付大約270美元的額外收入,每年至少有735名患者,同時及早發現和解決可以最大限度地減少或防止更昂貴的下游成本的問題。

Highmark earns a minimum of two months of monitoring per patient generating SaaS revenue of USD$60/patient/year. Highmark's model for orthopedic practices is a hybrid of recurring SaaS revenue with additional per patient use and implementation fees. During the initial USOA roll-out to 15 surgeons, Highmark anticipates generating an annual minimum of USD$50,000 per surgeon. Subsequent expansion of the roll-out to USOA's growing network of more than 100 surgeons will generate incremental set-up and recurring fees. The potential addressable market for the EQ Remote Monitoring Solution includes approximately 30,000 orthopedic surgeons in the United States alone.

Highmark為每個患者至少賺取兩個月的監測,產生每名患者/年60美元的SaaS收入。Highmark的整形外科實踐模式是經常性SaaS收入和每名患者額外的使用和實施費用的混合體。在最初向15名外科醫生推出USOA期間,Highmark預計每個外科醫生每年至少產生5萬美元的收入。隨後,將這項服務擴大到USOA不斷擴大的100多名外科醫生網絡,將產生額外的設置費用和經常性費用。EQ遠程監控解決方案的潛在市場僅在美國就包括大約30,000名整形外科醫生。

Highmark was also very excited to have launched Phase 1 of the THINK AHEAD Pathways Program with the Emergency Room ("ER") at Joseph Brant Hospital on June 14, 2022 with the program being deployed and live as of July 2022. In the first thirty days, we have received referrals for approximately 1.6 patients per day versus projections of 2 referrals per day. We believe through more engagement and awareness of the program we will be inline with our forecast of patient volumes.

Highmark還非常高興於2022年6月14日與Joseph Brant醫院的急診室(急診室)一起啟動了Think前瞻性路徑計劃的第一階段,該計劃已於2022年7月部署並上線。在最初的30天裏,我們每天收到大約1.6名患者的轉診,而不是預計每天2名轉診。我們相信,通過更多的參與和對該計劃的認識,我們將與我們對患者數量的預測保持一致。

This is the first of 13 additional ER's in the GTA expected before the end of 2023. The program offers physician follow-up and remote monitoring of neurological function to patients over the age of 12 and who have suffered a head injury. The physician can immediately review their current symptoms, balance and cognitive status using the Highmark telehealth portal, creating a more efficient clinical session without compromising quality.

這是預計在2023年底之前在GTA中增加的13個ER中的第一個。該計劃為12歲以上遭受頭部損傷的患者提供醫生跟蹤和神經功能遠程監測。醫生可以使用Highmark遠程醫療門户網站立即查看他們當前的症狀、平衡和認知狀態,從而在不影響質量的情況下創建更高效的臨牀會議。

Phase 1 deployments are anticipated to generate annualized recurring revenue of $3 million by fall of 2022. Phase 1 is anticipated to be an equal mix of SaaS revenue and clinical services. By the end of Q2 2023, the rollout schedule targets a total of 10 ER's generating approximately $10 million in annualized revenue, 75% consisting of SaaS revenue.

到2022年秋季,第一階段部署預計將產生300萬美元的年化經常性收入。第一階段預計將是SaaS收入和臨牀服務的等量組合。到2023年第二季度末,推廣計劃的目標是總共推出10個ER,年化收入約為1,000萬美元,其中75%來自SaaS收入。

Financial Highlights as at and for the Three and Six Months Ended June 30, 2022

截至2022年6月30日的三個月和六個月的財務摘要

*EBITDA is calculated as loss before income taxes, non-cash interest expense, accretion expense, share-based compensation, and depreciation and amortization.

*EBITDA計算為扣除所得税、非現金利息支出、增值支出、基於股份的薪酬以及折舊和攤銷前的虧損。

CEO Sanjeev Sharma notes, "The organization's hyper focus on its core technology streams is translating into accelerated on-boarding of Emergency Rooms. We believe this hyper-focused approach will support the SAAS revenue and EBITDA targets we've set over the next 12 months."

首席執行官Sanjeev Sharma指出:“該組織對其核心技術流的高度關注正在轉化為急診室的加速入職。我們相信這種高度專注的方法將支持我們在未來12個月設定的SAAS收入和EBITDA目標。”

Insider Financing in August 2022

2022年8月的內幕融資

On August 20th, the Company issued a CDN $1Million dollar 8% convertible note, paid semi-annually for a term of two years with a conversion price based on a future equity issuance. The funds will be used for the purposes of working capital to expedite sales and marketing initiatives for the THINK AHEAD pathways program and the continued expansion of HMRK's FDA approved EQ software into the U.S.

8月20日,公司發行了100萬加元8%的可轉換票據,每半年支付一次,期限為兩年,轉換價格基於未來的股票發行。這筆資金將用於營運資金,以加快Think Ahead Path計劃的銷售和營銷活動,並繼續將HMRK經FDA批准的EQ軟件擴展到美國。

About Highmark Interactive

關於Highmark Interactive

Highmark Interactive was created to change the paradigm of testing and management for brain and mental health. Highmark's approach is focused on providing real-time data to health providers to support proactive, preventative interventions and targeted care planning to improve health outcomes.

Highmark Interactive是為了改變大腦和心理健康的測試和管理模式而創建的。Highmark的方法側重於向衞生服務提供者提供實時數據,以支持積極主動的預防性幹預和有針對性的護理規劃,以改善衞生結果。

In addition to a growing network of virtual, in-person and hybrid clinics. Highmark Interactive offers the world's first gamified, FDA cleared patient-led assessments as well as digital clinician-led assessments of neurofunction and balance. Together. The technology is used in more than 350 health organizations globally.

除了不斷增長的虛擬、面對面和混合型診所網絡。Highmark Interactive提供了世界上第一個遊戲化的、FDA批准的患者主導的評估,以及數字臨牀醫生領導的神經功能和平衡評估。在一起。這項技術在全球350多個衞生組織中使用。

By unlocking insights, Highmark's platform enables precision medicine and creates a more contemporary model for delivering better outcomes in medical, mental health and rehabilitation services.

通過釋放洞察力,Highmark的平臺實現了精準醫療,並創建了一種更現代的模式,在醫療、心理健康和康復服務方面提供更好的結果。

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。“

Learn more:

瞭解更多情況:

For further information:

有關更多信息,請訪問:

Highmark Interactive Inc.
Sanjeev Sharma, President & CEO. sanjeev@highmark.tech or 1-855-969-5079

Highmark Interactive Inc.
桑吉夫·夏爾馬,總裁,首席執行官。電子郵件:sanjeev@Highmark.tech或1-855-969-5079

Investor Relations
ir@highmark.tech

投資者關係
郵箱:ir@Highmark.tech

SOURCE: Highmark Interactive Inc.

資料來源:Highmark Interactive Inc.


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論